Casares Jonathan A, Jaramillo Arturo P, Nizamudeen Sajidha, Abdul Samad Sanod Khan
Faculty of Medicine, Pontificia Universidad Católica del Ecuador, Quito, ECU.
General Practice, Universidad Estatal de Guayaquil, Machala, ECU.
Cureus. 2025 Apr 10;17(4):e82037. doi: 10.7759/cureus.82037. eCollection 2025 Apr.
Evolocumab is a PCSK9 inhibitor designed to significantly reduce low-density lipoprotein cholesterol (LDL-C) levels. Unlike statins, which work by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase to reduce cholesterol synthesis in the liver, evolocumab enhances LDL receptor recycling, leading to more efficient clearance of LDL-C from the bloodstream. Compared to placebo, evolocumab shows a profound LDL-C lowering effect while also offering incremental benefit over statins, especially in high-risk patients or those with statin intolerance. In this meta-analysis, the primary focus was on lipid-lowering efficacy and cardiovascular outcomes, making direct comparisons among evolocumab, statins, and placebo essential. Evolocumab consistently demonstrated a statistically significant reduction in LDL-C and, in several large-scale trials (such as Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER)), also showed a reduction in cardiovascular events, including myocardial infarction and stroke. It is important to specify that the most significant outcomes were both the substantial LDL-C reduction and the associated reduction in major adverse cardiovascular events (MACE). For our meta-analysis, we generated three graphical models using Review Manager (RevMan) version 5.4 (Cochrane Collaboration, Copenhagen, Denmark) based on the selected studies. To conduct our systematic review, we extensively examined a total of 10 articles. The subgroup analyses in these studies looked at how well evolocumab worked on its own, with statins, and as an extra treatment for people who were already taking low or high doses of statins. Additionally, we compared the effectiveness of evolocumab vs. placebo in both individuals with and without cardiovascular conditions. Our findings indicated that evolocumab, whether used as monotherapy or alongside statins, demonstrated statistical significance (p = 0.01). Moreover, all reviewed studies reported statistically significant results (p < 0.05). According to our analysis, there is an urgent need for more research to build on this body of evidence and carry out larger randomized controlled trials (RCTs) to find the best timing and dose for each patient and avoid any possible long-term side effects.
依洛尤单抗是一种前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂，旨在显著降低低密度脂蛋白胆固醇（LDL-C）水平。与通过抑制3-羟基-3-甲基戊二酰辅酶A还原酶来减少肝脏中胆固醇合成的他汀类药物不同，依洛尤单抗可增强LDL受体的再循环，从而更有效地从血液中清除LDL-C。与安慰剂相比，依洛尤单抗显示出显著的降低LDL-C的效果，同时相对于他汀类药物也有额外的益处，特别是在高危患者或对他汀类药物不耐受的患者中。在这项荟萃分析中，主要关注的是降脂疗效和心血管结局，因此对依洛尤单抗、他汀类药物和安慰剂进行直接比较至关重要。依洛尤单抗始终显示出LDL-C有统计学意义的降低，并且在几项大规模试验中（如进一步心血管结局研究：在高危受试者中抑制PCSK9（FOURIER）），还显示出心血管事件的减少，包括心肌梗死和中风。需要明确的是，最显著的结果是LDL-C的大幅降低以及主要不良心血管事件（MACE）的相应减少。对于我们的荟萃分析，我们使用Review Manager（RevMan）5.4版（丹麦哥本哈根的Cochrane协作网）根据所选研究生成了三个图形模型。为了进行我们的系统评价，我们广泛查阅了总共10篇文章。这些研究中的亚组分析考察了依洛尤单抗单独使用、与他汀类药物联合使用以及作为已经服用低剂量或高剂量他汀类药物患者的额外治疗时的效果。此外，我们比较了依洛尤单抗与安慰剂在有心血管疾病和无心血管疾病个体中的有效性。我们的研究结果表明，依洛尤单抗无论是作为单一疗法还是与他汀类药物联合使用，都具有统计学意义（p = 0.01）。此外，所有纳入综述的研究均报告了具有统计学意义的结果（p < 0.05）。根据我们的分析，迫切需要更多的研究以基于这一证据体系开展，并进行更大规模的随机对照试验（RCT），以找到适合每个患者的最佳时机和剂量，并避免任何可能的长期副作用。
